1. Immunology and Inflammation
Download icon

The somatically generated portion of the T cell receptor CDR3α contributes to the MHC allele specificity of the T cell receptor

  1. Philippa Marrack  Is a corresponding author
  2. Sai Harsha Krovi
  3. Daniel Silberman
  4. Janice White
  5. Eleanor Kushnir
  6. Maki Nakayama
  7. James Crooks
  8. Thomas Danhorn
  9. Sonia Leach
  10. Randy Anselment
  11. James Scott-Browne
  12. Laurent Gapin
  13. John Kappler
  1. Howard Hughes Medical Institute, National Jewish Health, United States
  2. University of Colorado School of Medicine, United States
  3. National Jewish Health, United States
  4. La Jolla Institute for Allergy and Immunology, United States
Research Article
  • Cited 13
  • Views 1,554
  • Annotations
Cite this article as: eLife 2017;6:e30918 doi: 10.7554/eLife.30918

Abstract

Mature T cells bearing αβ T cell receptors react with foreign antigens bound to alleles of major histocompatibility complex proteins (MHC) that they were exposed to during their development in the thymus, a phenomenon known as positive selection. The structural basis for positive selection has long been debated. Here, using mice expressing one of two different T cell receptor β chains and various MHC alleles, we show that positive selection-induced MHC bias of T cell receptors is affected both by the germline encoded elements of the T cell receptor α and β chain and, surprisingly, dramatically affected by the non germ line encoded portions of CDR3 of the T cell receptor α chain. Thus, in addition to determining specificity for antigen, the non germline encoded elements of T cell receptors may help the proteins cope with the extremely polymorphic nature of major histocompatibility complex products within the species.

Data availability

The following data sets were generated

Article and author information

Author details

  1. Philippa Marrack

    Howard Hughes Medical Institute, National Jewish Health, Denver, United States
    For correspondence
    MarrackP@NJHealth.org
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1883-3687
  2. Sai Harsha Krovi

    Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Daniel Silberman

    Department of Biomedical Research, National Jewish Health, Denver, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Janice White

    Department of Biomedical Research, National Jewish Health, Denver, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Eleanor Kushnir

    Department of Biomedical Research, National Jewish Health, Denver, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Maki Nakayama

    Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. James Crooks

    Division of Biostatistics and Bioinformatics, National Jewish Health, Denver, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Thomas Danhorn

    Division of Biostatistics and Bioinformatics, National Jewish Health, Denver, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3861-8602
  9. Sonia Leach

    Department of Biomedical Research, National Jewish Health, Denver, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Randy Anselment

    Division of Biostatistics and Bioinformatics, National Jewish Health, Denver, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. James Scott-Browne

    La Jolla Institute for Allergy and Immunology, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Laurent Gapin

    Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. John Kappler

    Howard Hughes Medical Institute, National Jewish Health, Denver, United States
    Competing interests
    The authors declare that no competing interests exist.

Funding

National Institutes of Health (AI 18785)

  • Philippa Marrack

National Institutes of Health (AI 092108)

  • Laurent Gapin

National Institutes of Health (AI 103736)

  • Laurent Gapin

Howard Hughes Medical Institute (NA)

  • John Kappler

National Institutes of Health (DK099317)

  • Maki Nakayama

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (AC-2517) of National Jewish Health. The protocol was approved by the Institutional Animal Care and Use Committee of National Jewish Health. Every effort was made to minimize suffering.

Reviewing Editor

  1. Pamela J Bjorkman, California Institute of Technology, United States

Publication history

  1. Received: August 1, 2017
  2. Accepted: November 16, 2017
  3. Accepted Manuscript published: November 17, 2017 (version 1)
  4. Version of Record published: November 24, 2017 (version 2)

Copyright

© 2017, Marrack et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,554
    Page views
  • 244
    Downloads
  • 13
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, Scopus, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

Further reading

    1. Immunology and Inflammation
    2. Microbiology and Infectious Disease
    Andreas Hober et al.
    Research Article Updated

    Reliable, robust, large-scale molecular testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential for monitoring the ongoing coronavirus disease 2019 (COVID-19) pandemic. We have developed a scalable analytical approach to detect viral proteins based on peptide immuno-affinity enrichment combined with liquid chromatography-mass spectrometry (LC-MS). This is a multiplexed strategy, based on targeted proteomics analysis and read-out by LC-MS, capable of precisely quantifying and confirming the presence of SARS-CoV-2 in phosphate-buffered saline (PBS) swab media from combined throat/nasopharynx/saliva samples. The results reveal that the levels of SARS-CoV-2 measured by LC-MS correlate well with their correspondingreal-time polymerase chain reaction (RT-PCR) read-out (r = 0.79). The analytical workflow shows similar turnaround times as regular RT-PCR instrumentation with a quantitative read-out of viral proteins corresponding to cycle thresholds (Ct) equivalents ranging from 21 to 34. Using RT-PCR as a reference, we demonstrate that the LC-MS-based method has 100% negative percent agreement (estimated specificity) and 95% positive percent agreement (estimated sensitivity) when analyzing clinical samples collected from asymptomatic individuals with a Ct within the limit of detection of the mass spectrometer (Ct ≤ 30). These results suggest that a scalable analytical method based on LC-MS has a place in future pandemic preparedness centers to complement current virus detection technologies.

    1. Immunology and Inflammation
    2. Structural Biology and Molecular Biophysics
    Mohamed A Badawy et al.
    Research Article

    Human serum albumin (HSA) is the frontline antioxidant protein in blood with established anti-inflammatory and anticoagulation functions. Here we report that COVID-19-induced oxidative stress inflicts structural damages to HSA and is linked with mortality outcome in critically ill patients. We recruited 39 patients who were followed up for a median of 12.5 days (1-35 days), among them 23 had died. Analyzing blood samples from patients and healthy individuals (n=11), we provide evidence that neutrophils are major sources of oxidative stress in blood and that hydrogen peroxide is highly accumulated in plasmas of non-survivors. We then analyzed electron paramagnetic resonance (EPR) spectra of spin labelled fatty acids (SLFA) bound with HSA in whole blood of control, survivor, and non-survivor subjects (n=10-11). Non-survivor' HSA showed dramatically reduced protein packing order parameter, faster SLFA correlational rotational time, and smaller S/W ratio (strong-binding/weak-binding sites within HSA), all reflecting remarkably fluid protein microenvironments. Following loading/unloading of 16-DSA we show that transport function of HSA maybe impaired in severe patients. Stratified at the means, Kaplan–Meier survival analysis indicated that lower values of S/W ratio and accumulated H2O2 in plasma significantly predicted in-hospital mortality (S/W≤0.15, 81.8% (18/22) vs. S/W>0.15, 18.2% (4/22), p=0.023; plasma [H2O2]>8.6 mM, 65.2% (15/23) vs. 34.8% (8/23), p=0.043). When we combined these two parameters as the ratio ((S/W)/[H2O2]) to derive a risk score, the resultant risk score lower than the mean (< 0.019) predicted mortality with high fidelity (95.5% (21/22) vs. 4.5% (1/22), logrank c2 = 12.1, p=4.9x10-4). The derived parameters may provide a surrogate marker to assess new candidates for COVID-19 treatments targeting HSA replacements and/or oxidative stress.